Results 41 to 50 of about 10,623 (204)

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

HIF-1α regulates CD55 expression in airway epithelium

, 2015
Indiana University-Purdue University Indianapolis (IUPUI)Rationale: CD55 down-regulation on airway epithelium correlates with local complement activation observed in hypoxia-associated pulmonary diseases.
Pandya, Pankita Hemant
core   +1 more source

Oncolytic Adenovirus CD55-Smad4 Suppresses Cell Proliferation, Metastasis, and Tumor Stemness in Colorectal Cancer by Regulating Wnt/β-Catenin Signaling Pathway

Biomedicines, 2020
During the past few decades, colorectal cancer (CRC) incidence and mortality have significantly increased, and CRC has become the leading cause of cancer-related death worldwide. Thus, exploring novel effective therapies for CRC is imperative.
Boduan Xiao, Leilei Zhang, Huihui Liu, Huiling Fang, Chunming Wang, Biao Huang, Xinyuan Liu, Xiumei Zhou, Yigang Wang   +8 more
doaj   +1 more source

Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology &Therapeutics, EarlyView.
Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji, Vincent Gagné, Émilie Espagne, Nathalie Alos, Veronica Del Vecchio, Lamia Ait Said, Albert Shalmiev, Claire Fuchs, Caroline Laverdière, Jean‐Marie Leclerc, Stephen E. Sallan, Lewis B. Silverman, Daniel Sinnett, Thai Hoa Tran, Maja Krajinovic   +14 more
wiley   +1 more source

Development of cancer immunotherapeutics targeting complement regulatory protein CD55 [PDF]

, 2007
CD55 is one of the complement regulatory/inhibitory proteins and is over-expressed on a wide range of solid tumours. CD55 is also known to be deposited within tumour stroma and is secreted in an active soluble form, mediated by matrix metalloproteinase-7.
Bradley, Richard Grayson
core  

Smart Nanodelivery Systems for Immunometabolic Modulation in Osteoarthritis

Exploration, EarlyView.
Smart nanodelivery systems deliver therapeutic payloads across the cartilage matrix to ensure their sustained accumulation within chondrocytes at sites of injury. By targeting specific molecular targets and signaling pathways, these platforms modulate the pathological synovium‐cartilage axis to restore immunometabolic homeostasis and drive tissue ...
Qirui Zhao, Zhewen Mi, Shuya Liu, Shijun Liang, Linjia Peng, Zixuan Gao, Jiaming Li, Xiaoqing Lu, Zhiguang Ren, Yongjie Wan, Shengsheng Cui, Longlong Lu, Xiaoyang Gao, Tao Wang, Hui Liang, Furong Tian, de la Fuente Jesus M, Chong Xiang, Luyi Sun, Lichen Xiang, Daxiang Cui   +20 more
wiley   +1 more source

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

Cells, 2022
Daratumumab (DARA) has improved the outcome of treatment of multiple myeloma (MM). DARA acts via complement-dependent and -independent mechanisms.
Kieran Brennan, Katrine F. Iversen, Alfonso Blanco-Fernández, Thomas Lund, Torben Plesner, Margaret M. Mc Gee   +5 more
doaj   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Hypoxia-Inducible Factor-1α Regulates CD55 in Airway Epithelium

, 2016
Airway epithelial CD55 down-regulation occurs in several hypoxia-associated pulmonary diseases, but the mechanism is unknown. Using in vivo and in vitro assays of pharmacologic inhibition and gene silencing, the current study investigated the role of ...
Gracon, Adam, Sandusky, George E., Pollok, Karen, Renbarger, Jamie, Pandya, Pankita H., Blum, Janice S., Murray, Mary, Lahm, Tim, Fisher, Amanda J., Temm, Constance J., Rothhaar, Katia, Lipking, Kelsey P., Mickler, Elizabeth A., Wilkes, David S.   +13 more
core   +1 more source

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Journal of Neuroinflammation, 2019
Background Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent ...
Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman   +3 more
doaj   +1 more source